A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged ≥65 years with community-acquired pneumonia

Clinical Therapeutics

Volumn 27, Issue 8, 2005, Pages 1251-1259

  Shorr, Andrew F ^a,d   Zadeikis, Neringa ^b,e   Xiang, Jim X ^b   Tennenberg, Alan M ^b,f   Wes Ely, E ^c  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b Ortho McNeil Pharmaceutical Incorporated   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d WASHINGTON HOSPITAL CENTER   (United States)

^e IQVIA   (United States)

^f Tibotec Therapeutics   (United States)

Author keywords

Community acquired pneumonia; Elderly; Levofloxacin; Outcomes

Indexed keywords

LEVOFLOXACIN;

ABDOMINAL PAIN; AGED; ARTICLE; COMMUNITY ACQUIRED PNEUMONIA; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED STUDY; DEMOGRAPHY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FEMALE; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGY; MULTIVARIATE ANALYSIS; NAUSEA; OUTCOMES RESEARCH; PERIPHERAL EDEMA; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MULTICENTER STUDIES; OFLOXACIN; PNEUMONIA; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 25844484135     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(05)80214-0     Document Type: Article

References (25)

1. Loeb M Pneumonia in older persons Clin Infect Dis 37 2003 1335 1339
2. Burt CW, and Schappert SM Ambulatory care visits to physician offices, hospital departments, and emergency departments: United States, 1999-2000 Vital Health Stat 13 157 2004 1 70
3. Popovic JR National Hospital Discharge Survey: Annual summary with detailed diagnosis and procedure data Vital Health Stat 13 151 2001 1 206
4. Janssens JP, and Krause KH Pneumonia in the very old Lancet Infect Dis 4 2004 112 124
5. Cunha BA Pneumonia in the elderly Clin Microbiol Infect 7 2001 581 588
6. Marrie TJ Epidemiology of community-acquired pneumonia in the elderly Semin Respir Infect 5 1990 260 268
7. Fine MJ, Smith MA, and Carson CA Prognosis and outcomes of patients with community-acquired pneumonia: A meta-analysis JAMA 275 1996 134 141
8. Kaplan V, Angus DC, and Griffin MF Hospitalized community-acquired pneumonia in the elderly: Age- and sex-related patterns of care and outcome in the United States Am J Respir Crit Care Med 165 2002 766 772
9. Niederman MS, Mandell LA, and Anzueto A the American Thoracic Society Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention Am J Respir Crit Care Med 163 2001 1730 1754
10. Mandell LA, Bartlett JG, and Dowell SF the Infectious Diseases Society of America Update of practice guidelines for the management of community-acquired pneumonia in immunocompetent adults Clin Infect Dis 37 2003 1405 1433
11. Vik SA, Maxwell CJ, and Hogan DB Measurement, correlates, and health outcomes of medication adherence among seniors Ann Pharmacother 38 2004 303 312
12. Gleason PP, Meehan TP, and Fine JM Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia Arch Intern Med 159 1999 2562 2572
13. [published correction appears in Clin Infect Dis. 2003;37:1147] Dunbar LM, Wunderink RG, and Habib MP High-dose, short-course levofloxacin for community-acquired pneumonia: A new treatment paradigm Clin Infect Dis 37 2003 752 760
14. Fine MJ, Auble TE, and Yealy DM A prediction rule to identify low-risk patients with community-acquired pneumonia N Engl J Med 336 1997 243 250
15. [published correction appears in Curr Med Res Opin. 2004; 20:967] Dunbar LM, Khashab MM, and Kahn JB Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogens Curr Med Res Opin 20 2004 555 563
16. Lode H, Grossman C, and Choudri S Sequential IV/PO moxifloxacin treatment of patients with severe community-acquired pneumonia Respir Med 97 2003 1134 1142
17. Correa JC, Badaro R, and Bumroongkit C Randomized, open-label, parallel-group, multicenter study of the efficacy and tolerability of IV gatifloxacin with the option for oral stepdown gatifloxacin versus IV ceftriaxone (with or without erythromycin or clarithromycin) with the option for oral stepdown clarithromycin for treatment of patients with mild to moderate community-acquired pneumonia requiring hospitalization Clin Ther 25 2003 1453 1468
18. File TM Jr, Segreti J, and Dunbar L A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia Antimicrob Agents Chemother 41 1997 1965 1972
19. Woods GL, Isaacs RD, McCarroll KA, and Friedland IR Ertapenem therapy for community-acquired pneumonia in the elderly J Am Geriatr Soc 51 2003 1526 1532
20. Preston SL, Drusano GL, and Berman AL Pharmacodynamics of levofloxacin: A new paradigm for early clinical trials JAMA 279 1998 125 129
21. Gotfried MH, Danziger LH, and Rodvold KA Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects Chest 119 2001 1114 1122
22. Stahlmann R, and Lode H Fluoroquinolones in the elderly: Safety considerations Drugs Aging 20 2003 289 302
23. Kushner JM, Peckman HJ, and Snyder CR Seizures associated with fluorquinolones Ann Pharmacother 35 2001 1194 1198
24. Noel GJ, Natarajan J, and Chien S Effects of three fluoroquinolones on QT interval in healthy adults after single doses Clin Pharmacol Ther 73 2003 292 303
25. Arce FC, Bhasin RS, and Pasmantier R Severe hyperglycemia during gatifloxacin therapy in patients without diabetes Endocr Pract 10 2004 40 44